wjpmr, 2024, 10(5), 139-142

SJIF Impact Factor: 6.842

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Review Article

ISSN 2455-3301

WJPMR

REVOLUTIONIZING TREATMENT ON MALARIA: A COMPREHENSIVE REVIEW OF MALARIA VACCINE

Dindayal Darunde*, Sandip Umare, Jija Lode, Amol Badkhal, Priti Chincholkar and Bharti Dhole

[1,2,3,4,5]Siddhivinayak College of Pharmacy Warora.
[6]Department of Pharmaceutical Sciences, RTMNU Nagpur.

***Corresponding Author: Dindayal Darunde**
Siddhivinayak College of Phamacy Warora.

Article Received on 08/03/2024 **Article Revised on 28/03/2024** **Article Accepted on 18/04/2024**

ABSTRACT

Malaria is a devastating disease that has plagued humanity for millennia. Despite accumulating circumstantial evidence suggesting a link between mosquitoes and malaria transmission, ancient civilizations did not comprehend the role of the parasite in spreading the disease. The development of a malaria vaccine has been a persistent challenge due to the complex nature of the malaria parasite and its ability to evade the immune system. Among the various malaria vaccine candidates undergoing clinical trials, the RTS, S vaccine has emerged as a frontrunner, having progressed from trials to implementation due to its promising results in reducing both clinical and severe cases of malaria. The complexity of developing a cost-effective vaccine against malaria, particularly in areas with moderate to high transmission rates, adds another layer of difficulty to the already challenging landscape of malaria vaccine development.

KEYWORDS: Malaria Vaccine, Clinical Trails, Malaria Treatment.

INTRODUCTION

A Historical Overview of Malaria

The historical record of malaria dates back thousands of years, with evidence of the disease's presence found in various ancient civilizations. Hindu texts from the sixth century BC, Egyptian papyri from 1570 BC, and Chinese documents from around 2700 BC all contain references to what is believed to be malaria, indicating its longstanding impact on human populations.[1] Moreover, ancient Greek figures such as Homer, Aristotle, and Hippocrates also made mentions of malaria in their works, highlighting the widespread recognition of the disease in antiquity.[2] Clay tablets from Mesopotamia dating back to 2000 BC and the Ebers Papyrus from 1200 years later further document the existence of malaria in early civilizations, providing valuable insights into the historical prevalence of the disease.[1,3] Additionally, the detection of malaria antigens in Egyptian remains from 3200 to 1304 BC reinforces the long history of malaria's impact on human populations.[2] The transmission of malaria to the Americas by European explorers and African slaves, leading to outbreaks in the Roman Empire and the 17th century, underscores the global reach and historical significance of this disease.[2,3] Overall, the earliest recorded cases of malaria, dating back approximately 7,000-12,000 years ago, highlight the enduring presence and impact of this ancient disease on human societies throughout history.[4]

Ancient civilizations perceive and treatment of Malaria

Ancient civilizations held diverse beliefs about the origins and treatments of malaria. Initially, the fever associated with malaria was attributed to supernatural forces and angry deities, showcasing a lack of understanding of the disease's true nature.[3] Hippocrates, in the 4th century BC, challenged the prevailing belief in demonic origins and connected malaria to evaporation from swamps, marking a significant shift in perception.[3] Despite accumulating circumstantial evidence suggesting a link between mosquitoes and malaria transmission, ancient civilizations did not comprehend the role of mosquitoes in spreading the disease.[1] Treatment methods for malaria in ancient times varied widely, ranging from blood-letting and limb amputations to the use of herbal medicines like belladonna for pain relief.[5] Additionally, preventive measures such as reducing contact with infected mosquitoes through avoidance and screening dwellings were employed to mitigate the risk of contracting malaria.[1] The introduction of prophylactic quinine and traditional herbal remedies like cinchona bark played a crucial role in ancient civilizations' efforts to combat malaria and alleviate its symptoms.[5] Despite the lack of comprehensive knowledge about malaria transmission, ancient civilizations employed a combination of treatments and

preventative measures to address the impact of this longstanding disease on human populations.

Historical events and Impact of Malaria on societies

Malaria has left an indelible mark on historical events and societies across the globe, shaping the course of nations and civilizations. From the impact of drug-resistant strains in Southeast Asia during the Vietnam War to the toll it took on soldiers during World War II, malaria has proven to be a formidable adversary that transcends borders and time periods.[2] The disease's influence extended to the founding of institutions like the Centers for Disease Control and Prevention, highlighting the necessity of organized efforts to combat its spread and effects.[2] Furthermore, the historical significance of malaria is underscored by its role in impeding colonization efforts in Africa, earning the region the moniker "the White Man's Grave" due to the high prevalence of tropical diseases like malaria.[2] Additionally, malaria's impact on the human genome through the development of sickle-cell disease showcases the intricate interplay between the parasite and the host's genetic makeup, further emphasizing the disease's multifaceted influence on societies throughout history.[4] As a disease that has plagued humanity for millennia, malaria's historical legacy serves as a testament to the resilience and ingenuity required to combat such formidable health challenges.[6]

Types of Malaria Vaccines

Malaria vaccine development has made significant strides, with various approaches targeting different stages of the parasite's lifecycle. Notably, the pre-erythrocytic stage has garnered attention, leading to the development of several potential vaccines focusing on this phase.[1] Currently, the two approved malaria vaccines are RTS,S and R-21/Matrix-M, with RTS,S being the only one demonstrating a protective effect against malaria thus far.[1,2] However, while progress has been made in pre-erythrocytic vaccines, efforts to develop effective blood-stage vaccines have not been as successful, with multiple candidates proving insufficient on their own.[1] In endemic areas, four types of malaria vaccines have undergone randomized controlled trials, targeting different stages of the parasite's lifecycle. Two of these vaccines, CS-NANP and RTS,S, specifically aim at the sporozoite stages of the Plasmodium parasite, while SPf66 and MSP/RESA vaccines target the asexual stages of the parasite.[3] Among these, RTS,S stands out as a recombinant protein-based vaccine that has completed late-stage development and is the first and only one to exhibit a protective effect against malaria.[2] Despite these advancements, a completely effective malaria vaccine is still elusive, highlighting the ongoing need for further research and development in this critical area of global health.

Mechanism of action of Malaria Vaccine

The mechanism of action of vaccines targeting different stages of malaria parasites varies significantly. For instance, type 1 vaccines aim to reduce severe malaria cases and deaths in high-transmission areas, such as sub-Saharan Africa, where infants and children are most vulnerable.[7] In contrast, type 2 vaccines are designed to prevent all clinical symptoms in individuals with no previous exposure, making them suitable for travelers seeking protection against malaria.[7] Additionally, fractional dosing regimens have been implemented to enhance efficacy against controlled human malaria infection (CHMI) by administering a reduced dosage for the final vaccine administration.[10] This strategy aims to maximize immunity while minimizing adverse reactions. Furthermore, seasonal vaccination with vaccines like RTS,S, coupled with annual booster doses during peak malaria parasite transmission, seeks to optimize antibody responses at critical times when exposure to the parasite is most likely.[10] These targeted approaches align with the complex lifecycle of malaria parasites, which poses challenges in understanding the immune response dynamics and necessitates tailored vaccination strategies to combat the disease effectively.[11]

Malaria vaccine in clinical trials

Among the various malaria vaccine candidates undergoing clinical trials, the RTS,S vaccine has emerged as a frontrunner, having progressed from trials to implementation due to its promising results in reducing both clinical and severe cases of malaria. Specifically, the RTS,S vaccine has demonstrated a significant reduction of about one-third in malaria cases among 5-17-month-old children, showcasing its potential as an effective intervention against the deadly P. falciparum parasite.[10,11] However, despite its success in older children, the RTS,S vaccine exhibited less efficacy in young infants, emphasizing the need for further research and development to enhance its effectiveness across different age groups.[10,11] While the RTS,S vaccine shows promise, ongoing studies are essential to address any safety concerns identified during the trials, ensuring its suitability for widespread use in malaria-endemic regions.[11] In contrast to blood-stage candidates, which have waned in interest due to disappointing human efficacy results, whole sporozoite vaccines have displayed encouraging outcomes in clinical trials, offering hope for improved malaria prevention strategies.[10] Additionally, novel formulations, such as P. falciparum serine repeat antigen-5 with aluminium hydroxide (BK-SE36), have exhibited evidence of protection against parasitemia infections and symptomatic episodes, underscoring the potential of innovative approaches in malaria vaccine development.[12]

Development of Malaria Vaccines

Approaches in developing malaria vaccines

Developing a successful malaria vaccine has been a persistent challenge due to the complex nature of the malaria parasite and its ability to evade the immune system. Various strategies have been explored to tackle this issue, including pre-erythrocytic vaccines, antibody-

based subunit vaccines, vectored vaccines, whole sporozoite vaccines, genetically attenuated parasites, and sporozoite subunit vaccines, among others.[13] Despite the introduction of multiple approaches, the success of malaria vaccine development has been limited, highlighting the need for further research and evaluation of vaccine candidates through clinical trials.[13] The intricate life cycle of the malaria parasite, with its complex and diverse genomes, as well as immune evasion mechanisms, pose significant challenges in developing an effective vaccine for falciparum malaria.[13] Additionally, the variability of antigens within each stage of the parasite and the requirement of T-cell immunity for protection have further complicated vaccine development.[13] To address these challenges, scientists are considering combining multiple approaches and exploring alternative parasite targets to enhance the efficacy of malaria vaccines.[13,14] It is essential to continue research efforts and consider factors such as the pathogen's life cycle, antigen candidates, and preclinical/clinical results to advance the development of effective malaria vaccines.[13]

Past clinical trials influenced the current development of malaria vaccines

The development of malaria vaccines has seen significant advancements in recent years, owing much to the lessons learned from past clinical trials. Since the 1960s, when efforts to create a malaria vaccine began, substantial progress has been made, particularly in the last decade.[15] Researchers have shifted their focus from live attenuated vaccines to isolating and delivering specific antigens, a move influenced by past clinical trials conducted in 2002.[13] Additionally, the understanding that the malaria parasite has three distinct life stages has led to the investigation of three different vaccine approaches to target each stage effectively.[13] Clinical trials, including Phase 3 testing of RTS,S, have prompted an increase in the evaluation of other pre-erythrocytic candidates like whole sporozoite vaccines.[16] Despite setbacks in human efficacy results, new blood-stage targets and concepts are being explored, potentially reviving interest in this area of vaccine development.[16] Moreover, advancements in antigen discovery, human monoclonal antibodies, structural vaccinology, and improved platforms are expected to enhance existing vaccine candidates based on past clinical trial outcomes, showcasing the importance of learning from previous research endeavors in shaping current vaccine development strategies.[16]

Challenges faced in developing an effective malaria vaccine

Developing an effective malaria vaccine faces a multitude of challenges that impede progress in combatting this deadly disease. The technical intricacy involved in creating a vaccine against a parasite, as opposed to a virus, poses a significant hurdle in the development of an efficacious malaria vaccine.[15] Furthermore, the lack of a traditional market for malaria vaccines discourages many developers from investing in this area of research, leading to limited funding and research initiatives allocated towards malaria vaccine development.[15,17] Despite the necessity highlighted since the identification of the malaria parasite in 1897, the focus of manufacturers on industrialized first-world markets rather than malaria-endemic countries further exacerbates the challenge of vaccine development for regions most in need.[17,13] Additionally, the emergence of resistant parasites and vectors has shifted attention towards alternative control methods, diverting resources away from vaccine development.[13] The complexity of developing a cost-effective vaccine against malaria, particularly in areas with moderate to high transmission rates, adds another layer of difficulty to the already challenging landscape of malaria vaccine development. In light of these obstacles, public-private partnerships such as the Malaria Vaccine Initiative offer a glimmer of hope for advancing malaria research and potentially overcoming these challenges in the future.[17]

CONCLUSION

The development of a malaria vaccine has been a persistent challenge due to the complex nature of the malaria parasite and its ability to evade the immune system. However, among the various malaria vaccine candidates, the RTS, S vaccine has emerged as a frontrunner, showing promising results in reducing both clinical and severe cases of malaria. Despite advancements in pre-erythrocytic vaccines, efforts to develop effective blood-stage vaccines have been less successful. Malaria has left a significant historical impact on societies across the globe, shaping the course of nations and civilizations. It has impeded colonization efforts, affected historical events like wars, and influenced the human genome through the development of sickle-cell disease. The mechanism of action of malaria vaccines varies depending on the stage targeted and the population being vaccinated, such as reducing severe cases or preventing clinical symptoms in non-exposed individuals. The development of malaria vaccines has faced challenges, including the complexity of the parasite, limited funding and research initiatives, and the emergence of resistant parasites and vectors. Despite these challenges, ongoing research and evaluation of vaccine candidates remain essential to advance the development of effective malaria vaccines.

REFERENCES

1. Cox FE. History of the discovery of the malaria parasites and their vectors. Parasites & vectors, 2010 Dec; 3: 1-9.
2. Gelband H, Panosian CB, Arrow KJ, editors. Saving lives, buying time: economics of malaria drugs in an age of resistance.
3. Talapko J, Škrlec I, Alebić T, Jukić M, Včev A. Malaria: the past and the present. Microorganisms, 2019 Jun 21; 7(6): 179.
4. *History of malaria*. (n.d.) retrieved April 9, 2024. from en.wikipedia.org/wiki/History_of_malaria.

5. *A Brief History of Malaria and Its Treatment*. (n.d.) retrieved April 9, 2024. from sites.duke.edu.
6. *Malaria vaccine*. (n.d.) retrieved April 10, 2024. from en.wikipedia.org/wiki/Malaria_vaccine.
7. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. The lancet, 2004 Jan 10; 363(9403): 150-6.
8. Graves PM, Gelband H, Cochrane Infectious Diseases Group. Vaccines for preventing malaria (SPf66). Cochrane Database of Systematic Reviews, 1996 Sep 1; 2019(5).
9. Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines, 2020 Jun 9; 5(1): 48.
10. Laurens MB. RTS, S/AS01 vaccine (Mosquirix™): an overview. Human vaccines & immunotherapeutics, 2020 Mar 3; 16(3): 480-9.
11. Stanisic DI, Good MF. Malaria vaccines: progress to date. BioDrugs, 2023 Nov; 37(6): 737-56.
12. Mahmoudi S, Keshavarz H. Malaria vaccine development: the need for novel approaches: a review article. Iranian journal of parasitology, 2018 Jan; 13(1): 1.
13. *Malaria*. (n.d.) retrieved April 9, 2024. from historyofvaccines.org/diseases/malaria/
14. *Vaccines*. (n.d.) retrieved April 9, 2024. from www.cdc.gov/malaria/malaria_worldwide /reduction/vaccine.html
15. Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines. 2020 Jun 9; 5(1): 48.
16. El-Moamly AA, El-Sweify MA. Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects. Tropical Medicine and Health, 2023 May 17; 51(1): 29.
17. World Health Organization. WHO recommends groundbreaking malaria vaccine for children at risk. World Health Organization, 2021 Oct 6; 1.